Jyong BiotechMENS +6.47%10 EV-to-FCF is -214.07 as of Jul. 02, 2026. GuruFocus rates MENS with a GF Score™ of 10/100. The stock has 3 warning signs investors should review. Among 333 Biotechnology companies, Jyong Biotech ranks worse than 300300% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Jyong Biotech's Enterprise Value is $182.17 Mil.
Jyong Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.85 Mil. Therefore, Jyong Biotech's EV-to-FCF for today is -214.07.
The historical rank and industry rank for Jyong Biotech's EV-to-FCF or its related term are showing as below:
MENS'
s EV-to-FCF Range Over the Past 10 Years
Min: -225.41 Med: 0 Max: 0
Current: -214.07
MENS's EV-to-FCF is ranked worse than 100% of 333
companies
in the Biotechnology industry
Industry Median: 15.57
vs MENS: -214.07
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Jyong Biotech's PE Ratio (TTM) for today is calculated as:
Jyong Biotech's share price for today is $2.22.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Jyong Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.060.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Jyong Biotech EV-to-FCF Related Terms
Jyong Biotech EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Jyong Biotech's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Jyong Biotech's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jyong Biotech EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jyong Biotech's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Jyong Biotech's EV-to-FCF falls into.
Jyong Biotech's current Enterprise Value is $182.17 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Jyong Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.85 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jyong Biotech (MENS) has a EV-to-FCF of -214.07 as of Jul. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Jyong Biotech and its competitors. According to the industry distribution chart, Jyong Biotech ranks #999999 out of 333 companies in the Biotechnology industry.
Is Jyong Biotech's EV-to-FCF too high?
Jyong Biotech's current EV-to-FCF is -214.07. Based on the distribution chart, Jyong Biotech ranks #999999 out of 333 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Jyong Biotech has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Jyong Biotech's EV-to-FCF compare to ENLV and CNTB?
According to the Biotechnology industry distribution chart, Jyong Biotech ranks #999999 out of 333 companies for EV-to-FCF. This places Jyong Biotech in the lower half of its industry. The industry median EV-to-FCF is 15.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.57, based on 333 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Jyong Biotech and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jyong Biotech's current EV-to-FCF is -214.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jyong Biotech stock overvalued right now?
Jyong Biotech (MENS) has a current EV-to-FCF of -214.07. The current EV-to-FCF is -214.07. Jyong Biotech's overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Jyong Biotech (MENS), the current EV-to-FCF is -214.07 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Jyong Biotech Ltd is research and develop new drugs for today's great unmet medical needs and planned to manufacture and sell new drugs after receiving regulatory approval. It is a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. The Group operates and manages its business as a single segment in the research and development of novel therapeutics targeting unmet needs. The company's product pipeline includes MCS-2, PCP, IC.
10GF Score
Get the complete analysis for MENS
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MENS has been successfully added to your 